Clinical Trial

A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant refractory/relapsed gastrointestinal tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2025-12-30 -> 2027-12-30 2026-08-06
minor Completion pushed: 2026-07-30 -> 2029-07-30 2026-08-06
Trial Details
NCT Number NCT04960072
Lead Sponsor Shanghai Juncell Therapeutics
Collaborators: Shanghai 10th People's Hospital
Conditions Gastrointestinal Tumor
Enrollment 50 participants
Start Date 2021-06-30
Primary Completion 2027-12-30 (estimated)
Study Completion 2029-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-05